Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive cancer and may become the second leading cause of cancer death by 2030. About half of the patients are diagnosed late, when the cancer has already spread (mPDAC), and the outlook is very poor. Chemotherapy is currently the only treatment for mPDAC. It can slow the disease and slightly extend life, but usually only by a few months. There are no other treatments that clearly improve survival. Radiofrequency ablation (RFA) is a minimally invasive technique that uses high-frequency electrical energy to generate heat and destroy tumor cells. Radiofrequency energy raises the temperature of the tissue, leading to coagulative necrosis and tumor cell death. RFA is commonly used to treat certain types of cancer and pre-cancerous lesions, including liver, kidney, lung, and bone tumors. In addition to directly destroying tumor tissue, RFA may also enhance the immune system's ability to recognize and attack cancer cells by exposing tumor antigens that were previously hidden within the tumor mass. Most research on radiofrequency ablation (RFA) to date has focused on Barrett's esophagus and liver cancer. However, RFA is increasingly being explored in palliative care, where early results suggest potential benefits. Advances in miniaturized endoscopic technology have enabled the application of RFA in anatomically challenging locations, such as the bile duct. Studies, including case series and clinical trials, have demonstrated that RFA is both feasible and safe. However, its impact on overall survival remains uncertain. Many previous studies are limited by small sample sizes and heterogeneous populations, often including patients with different cancer types and disease stages, which introduces bias and limits the generalizability of findings. We have therefore designed a prospective study focusing on patients with bile duct obstruction due to pancreatic ductal adenocarcinoma (PDAC) with limited metastatic spread (oligometastatic mPDAC). This study aims to provide more robust evidence on the potential role of RFA in improving clinical outcomes in a carefully selected subset of patients with advanced PDAC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowo zdiagnozowany rak trzustki w głowie trzustki, który uciska przewód żółciowy
- •Przerzuty do wątroby (maksymalnie 5 przerzutów, każdy do 1 cm średnicy)
- •Potwierdzony histologicznie lub cytologicznie zaawansowany rak trzustki
- •Pacjent otrzymuje chemioterapię paliatywną
- •Wiek 18-85 lat
- •Ogólny stan zdrowia pozwalający na udział w badaniu (skala WHO 0-2)
✗ Disqualifies
- •Problemy ze zrozumieniem instrukcji lub niemożliwość wyrażenia świadomej zgody
- •Poważne zaburzenia układu odpornościowego lub niskie liczby białych krwinek/płytek
- •Obecna ostра infekcja przewodów żółciowych lub posocznica
- •Ostra niewydolność nerek
- •Poważne problemy z sercem lub niestabilna niedokrwienność
- •Ciąża lub karmienie piersią
- •Przerzuty poza wątrobę
- •Rozrusznik serca lub kardiowerter-defibrylatор
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 85 Years
- Last updated (source)
- August 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Department of Surgery, Umeå University Hospital
Umeå, Sweden
Trial contact
Roberto Valente, MD, PHD, Head of Surgical Endo
Ira Sotirova, MD, GI surgeon
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/25/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.